D
David C. Reutens
Researcher at University of Queensland
Publications - 367
Citations - 11854
David C. Reutens is an academic researcher from University of Queensland. The author has contributed to research in topics: Epilepsy & Cognition. The author has an hindex of 55, co-authored 356 publications receiving 10668 citations. Previous affiliations of David C. Reutens include Royal Perth Hospital & Royal Melbourne Hospital.
Papers
More filters
Journal ArticleDOI
The amygdala and sexual drive: Insights from temporal lobe epilepsy surgery
TL;DR: A relationship between contralateral amygdalar volume and sexual outcome in patients undergoing temporal lobe resection is demonstrated and provides evidence for an important role of the amygdala in regulating human sexual behavior.
Journal ArticleDOI
α-[11C]-Methyl-l-tryptophan PET identifies the epileptogenic tuber and correlates with interictal spike frequency
Marco Fedi,David C. Reutens,Frederick Andermann,Hidehiko Okazawa,Warren Boling,Carole L. White,François Dubeau,Akio Nakai,Donald W. Gross,Eva Andermann,Mirko Diksic +10 more
TL;DR: In this paper, the alpha-methyl-L-tryptophan (MTrp) uptake was measured in 8 patients with intractable partial epilepsy due to tuberous sclerosis complex (TSC).
Journal ArticleDOI
Hippocampal 5-HT1A Receptor and Spatial Learning and Memory
TL;DR: Evidence from recent cognitive imaging studies using positron emission tomography with 5-HT1A receptor ligands, and studies of individual genetic variance in 5- HT1A receptors availability, strongly suggests that 5-hydroxytryptamine, mediated by the 4A receptor subtype, plays a key role in spatial learning and memory.
Journal ArticleDOI
Lateralizing value of peri-ictal headache: A study of 100 patients with partial epilepsy.
TL;DR: To determine the lateralizing value of peri-ictal headache, the authors conducted a standardized interview of 100 patients with partial epilepsy, 60 with temporal lobe epilepsy (TLE) and 40 with extratemporal epilepsy (ETE).
Journal ArticleDOI
Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy.
TL;DR: In patients with progressive myoclonus epilepsy, the efficacy of the drug increased during the first 12 months of treatment and then stabilized, and Piracetam given as add-on therapy seems to be an effective, sustained, and well-tolerated treatment of myOClonus.